Claims for Patent: 9,138,458
✉ Email this page to a colleague
Summary for Patent: 9,138,458
Title: | Treatment for dupuytren\'s disease |
Abstract: | Musculoskeletal fibroproliferative disorders, such as Dupuytren\'s disease may be treated by administering locally a TNF-.alpha. antagonist. TNF-.alpha. antagonists find particular utility in inhibiting the progression of early disease state Dupuytren\'s disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such ascollagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren\'s disease and, in particular inhibiting recurrence. |
Inventor(s): | Nanchahal; Jagdeep (Richmond, GB), Midwood; Kim Suzanne (London, GB) |
Assignee: | Isis Innovation Limited (Oxford, GB) |
Application Number: | 13/882,262 |
Patent Claims: | 1. A method for treating a patient with early disease state Dupuytren's disease comprising injecting an amount of a TNF-.alpha. antagonist effective to treat the
patient directly into one or more clinical or histological nodules of the patient.
2. A method according to claim 1, wherein the TNF-.alpha. antagonist is selected from one or more of Infliximab, Adalimumab, Certolizumab pegol, Golimumab or Etanercept. 3. A method according to claim 1, wherein the TNF-.alpha. antagonist is an anti-TNF-.alpha. antibody. 4. A method according to claim 1, wherein the TNF-.alpha. antagonist is injected into clinical nodules. 5. A method according to claim 1, wherein the TNF-.alpha. antagonist is Infliximab. 6. A method according to claim 1, wherein the TNF-.alpha. antagonist is Adalimumab. 7. A method according to claim 1, wherein the TNF-.alpha. antagonist is Certolizumab pegol. 8. A method according to claim 1, wherein the TNF-.alpha. antagonist is Golimumab. 9. A method according to claim 1, wherein the TNF-.alpha. antagonist is Etanercept. |
Details for Patent 9,138,458
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2030-10-30 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2030-10-30 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2030-10-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.